Miulescu, Rucsandra Dӑnciulescu; Muşat, Mӑdalina; Dӑnoiu, Suzana; Poianӑ, Cӑtӑlina; Dumitrache, C.
September 2009
Therapeutics, Pharmacology & Clinical Toxicology;2009, Vol. 13 Issue 3, p315
Academic Journal
The metabolic syndrome is comprised of several cardiovascular risk factors such as central obesity, hyperglycemia, hypertension and hyperlipidemia, most probably pathogenically correlated. Patients with schizophrenia have an increased risk of developing metabolic syndrome due to inappropriate physical activity, disorders of food intake or secondary to antipsychotic medication. Due to the increased prevalence of metabolic syndrome and diabetes mellitus in patients with schizophrenia, the American Association of Psychiatry recommends screening and follow-up for metabolic risk factors. Thus the recommendation is to assess fasting glycemia and glycated hemoglobin at 4 month s from commencement of a new drug therapy, then annually. BMI has to be monitored every 3 to 6 month s. Except for the patients with a BMI below 18.5, every increment of their BMI of 1kg/m2 should be followed by either a change in antipsychotic medication or the admission of the patient in a weight control program.


Related Articles

  • Effect of Nurse Case Management Compared With Usual Care on Controlling Cardiovascular Risk Factors in Patients With Diabetes. ISHANI, AREEF; GREER, NANCY; TAYLOR, BRENT C.; KUBES, LAURIE; COLE, PAULA; ATWOOD, MELISSA; CLOTHIER, BARBARA; ERCAN-FANG, NACIDE // Diabetes Care;Aug2011, Vol. 34 Issue 8, p1689 

    OBJECTIVE--To determine whether nurse case management with a therapeutic algorithm could effectively improve rates of control for hypertension, hyperglycemia, and hyperlipidemia compared with usual care among veterans with diabetes. RESEARCH DESIGN AND METHODS--A randomized controlled trial of...

  • Adiposity and Insulin Sensitivity Derived from Intravenous Glucose Tolerance Tests in Antipsychotic-Treated Patients. Haupt, Dan W.; Fahnestock, Peter A.; Flavin, Karen A.; Schweiger, Julie A.; Stevens, Angela; Hessler, Martha J.; Maeda, Justin; Yingling, Michael; Newcomer, John W. // Neuropsychopharmacology;Dec2007, Vol. 32 Issue 12, p2561 

    Cardiovascular disease is more common in schizophrenia patients than in the general population, with a hypothesized contribution from increases in adiposity produced by antipsychotic medications. We sought to test the relationship between adiposity and insulin resistance using frequently sampled...

  • Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual-energy X-ray absorptiometry in Japanese individuals. Ito, H; Nakasuga, K; Ohshima, A; Maruyama, T; Kaji, Y; Harada, M; Fukunaga, M; Jingu, S; Sakamoto, M // International Journal of Obesity & Related Metabolic Disorders;Feb2003, Vol. 27 Issue 2, p232 

    OBJECTIVE:: To determine the cut-off points of indices of obesity for detecting hypertension, dyslipidemia and diabetes mellitus in Japanese individuals. DESIGN:: Cross-sectional study. SUBJECTS:: A total of 2728 Japanese individuals (768 males and 1960 females, aged 20–79 y) who attended...

  • Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Liao, Katherine P.; Solomon, Daniel H. // Rheumatology;Jan2013, Vol. 52 Issue 1, p45 

    Multiple studies demonstrate an increased cardiovascular (CV) risk associated with RA compared with the general population. While part of this risk appears to be mediated by RA-specific factors, such as long-term inflammation, traditional CV comorbidities also play an important role. We review...

  • Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Ader, Marilyn; Kim, Stella P.; Catalano, Karyn J.; Ionut, Viorica; Hucking, Katrin; Richey, Joyce M.; Kabir, Morvarid; Bergman, Richard N. // Diabetes;Mar2005, Vol. 54 Issue 3, p862 

    Atypical antipsychotics have been linked to weight gain, hyperglycemia, and diabetes. We examined the effects of atypical antipsychotics olanzapine (OLZ) and risperidone (RIS) versus placebo on adiposity, insulin sensitivity (S(I)), and pancreatic beta-cell compensation. Dogs were fed ad libitum...

  • Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. Gordon, Pedro Caldana; Xavier, Josefa Cynara; Louzã, Mario Rodrigues // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p133 

    Background: In the last few decades, a large number of studies have produced compelling evidence that patients with schizophrenia are at increased risk for developing several medical conditions and diseases, including obesity, metabolic disturbances, and cardiovascular diseases. Several...

  • Antipsychotics can increase metabolic risk factors. Fernandez, Julio // Drug Topics;6/18/2007, Vol. 151 Issue 12, p19 

    The article reports on the metabolic risks of schizophrenics taking atypical antipsychotics in the U.S. It states that atypical antipsychotics have been used as an effective drug for schizophrenia, however, it was found to be associated with a high incidence of weight gain. The Clinical...

  • Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. Okon, Elena B.; Chung, Ada W.Y.; Zhang, Hongbin; Laher, Ismail; van Breemen, Cornelis // Canadian Journal of Physiology & Pharmacology;May2007, Vol. 85 Issue 5, p562 

    Diabetes mellitus impairs endothelial function, which can be considered as the hallmark in the development of cardiovascular diseases. Hyperglycemia, hyperinsulinemia, and hyperlipidemia are believed to contribute to endothelial dysfunction. In the present study, we investigated the possible...

  • Diabetes, the Metabolic Syndrome, and Ischemic Stroke. Air, Ellen L.; Kissela, Brett M. // Diabetes Care;Dec2007, Vol. 30 Issue 12, p3131 

    The article explores the potential underlying mechanisms that lead to increased incidence of stroke among patients with diabetes. It examines the impact of diabetes and hyperglycemia on stroke outcomes and discusses the current approaches to reduce stroke in the high-risk population. It says...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics